Takeda Pharmaceutical Co Ltd ADR
$ 17.45
2.53%
07 Aug - close price
- Market Cap 55,726,629,000 USD
- Current Price $ 17.45
- High / Low $ 17.56 / 17.41
- Stock P/E N/A
- Book Value 14.36
- EPS -0.34
- Next Earning Report -
- Dividend Per Share $200.00
- Dividend Yield 3.62 %
- Next Dividend Date -
- ROA 0.03 %
- ROE -0.02 %
- 52 Week High 18.90
- 52 Week Low 12.78
About
Takeda Pharmaceutical Company Limited is engaged in the research, development, manufacture and marketing of pharmaceuticals, over-the-counter drugs and quasi-drug consumer products, and other health care products. The company is headquartered in Tokyo, Japan.
Analyst Target Price
$21.59
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Previous Dividend Records
| Jul 2026 | Dec 2025 | Jul 2025 | Dec 2024 | Jul 2024 | Dec 2023 | Jul 2023 | Dec 2022 | Jul 2022 | Jul 2021 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Payment Date | 2026-07-06 | 2025-12-11 | 2025-07-07 | 2024-12-12 | 2024-07-08 | 2023-12-11 | 2023-07-10 | 2022-12-12 | 2022-07-11 | 2021-07-12 |
| Amount | $0.308273 | $0.322144 | $0.33901 | $0.326079 | $0.292214 | $0.319068 | $0.30996 | $0.329553 | $0.330062 | $0.406627 |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: TAK
2026-08-08 12:10:18
The FDA recently approved Takeda Pharmaceutical's ORZEYFUL for narcolepsy type 1, providing a new entry into a rare disease market addressing orexin deficiency. While this approval strengthens Takeda's pipeline narrative, management has indicated it won't significantly alter this year's financial forecast. Investors should focus on broader late-stage data and launches, as the company faces patent erosion and increased R&D spending, despite projections of revenue and earnings growth by 2029.
2026-08-06 16:41:37
Takeda's oral orexin receptor agonist, oveporexton (marketed as Orzeyful), has received FDA approval for narcolepsy type 1, making it the first disease-modifying therapy for the condition. The drug targets the root cause of narcolepsy by binding to the orexin receptor 2, improving wakefulness and other symptoms. While Takeda gains a first-to-market advantage, it faces future competition from other companies developing similar orexin receptor agonists.
2026-08-06 16:40:34
The FDA has approved Takeda's Orzeyful, a drug for Type 1 narcolepsy that targets orexin-2 protein. This approval marks the entry of a potentially multibillion-dollar class of sleep medicines. Orzeyful's launch is pending DEA scheduling, while other companies like Alkermes and Eli Lilly are also developing similar orexin-boosting drugs for various sleep disorders.
2026-08-06 15:40:35
Takeda has received FDA approval for Orzeyful (oveporexton), a first-in-class, twice-daily tablet for adults with narcolepsy type 1 (NT1). This treatment addresses the root cause of the condition by mimicking the body's orexin cycle. Takeda anticipates peak sales for Orzeyful to be between $2 billion and $3 billion and expects to launch it after DEA classification, which is projected within 90 days.
2026-08-06 15:40:35
Takeda Pharmaceutical has received U.S. FDA approval for ORZEYFUL (oveporexton) to treat adults with narcolepsy type 1, making it the first approved orexin agonist for the disorder. The approval, granted on August 5, 2026, is based on positive Phase 3 trial results showing significant improvements in symptoms like excessive daytime sleepiness and cataplexy. Takeda plans a U.S. launch after a DEA scheduling review, expected within 90 days.
2026-08-06 10:40:34
The FDA has approved Takeda's Orzeyful (oveporexton) as the first medication to directly address the loss of orexin signaling in Narcolepsy Type 1. Unlike previous treatments that only offered symptomatic relief, Orzeyful targets the underlying cause by activating the brain's orexin receptor 2 (OX2R). This approval, based on positive Phase III study results, offers a new approach to managing the full range of symptoms for the estimated 120,000 people living with Narcolepsy Type 1 in the US.
